Meeder Asset Management Inc Alaunos Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.12 - $0.5 $513 - $2,140	-4,281 Reduced 87.35%	620 $0
Q1 2023 May 15, 2023	SELL	$0.46 - $0.81 $2,346 - $4,132	-5,102 Reduced 51.0%	4,901 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $261.0 $1,992 - $1.04 Million	-3,984 Reduced 28.48%	10,003 $6,000
Q2 2022 Aug 08, 2022	SELL	$0.41 - $1.24 $451 - $1,364	-1,100 Reduced 7.29%	13,987 $17,000
Q1 2022 May 10, 2022	BUY	$0.62 - $1.17 $9,353 - $17,651	15,087 New	15,087 $9,000
Q4 2021 Feb 11, 2022	SELL	$1.09 - $1.89 $5,805 - $10,066	-5,326 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$2.82 - $5.6 $15,019 - $29,825	5,326 New	5,326 $19,000
Q4 2020 Feb 09, 2021	SELL	$2.09 - $3.09 $15,357 - $22,705	-7,348 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$2.39 - $3.43 $17,561 - $25,203	7,348 New	7,348 $19,000
Q1 2019 Apr 16, 2019	SELL	$2.0 - $4.4 $1,244 - $2,736	-622 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$1.61 - $3.62 $112 - $253	70 Added 12.68%	622 $1,000
Q3 2018 Nov 02, 2018	BUY	$2.26 - $3.27 $1,247 - $1,805	552 New	552 $0

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.